News
RAPT
8.98
+0.56%
0.05
Rapt Therapeutics Price Target Cut to $13.00/Share From $15.00 by JP Morgan
Dow Jones · 2d ago
Rapt Therapeutics Is Maintained at Neutral by JP Morgan
Dow Jones · 2d ago
JP Morgan Maintains Neutral on RAPT Therapeutics, Lowers Price Target to $13
Benzinga · 2d ago
Weekly Report: what happened at RAPT last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at RAPT last week (0311-0315)?
Weekly Report · 03/18 11:35
Weekly Report: what happened at RAPT last week (0304-0308)?
Weekly Report · 03/11 11:31
Hold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concerns
TipRanks · 03/11 04:46
RAPT Therapeutics Inc <RAPT.OQ> expected to post a loss of 80 cents a share - Earnings Preview
RAPT Therapeutics Inc expected to post a loss of 80 cents a share. The company is expected to show change in quarterly revenue when it reports results on May 9. The average analyst rating on the shares is "buy" and the median 12-month price target is $19.50.
Reuters · 03/08 13:13
H.C. Wainwright Remains a Hold on RAPT Therapeutics (RAPT)
TipRanks · 03/08 11:30
Analysts Conflicted on These Healthcare Names: RAPT Therapeutics (RAPT), Eli Lilly & Co (LLY) and Sight Sciences (SGHT)
TipRanks · 03/08 10:41
RAPT Stock Earnings: RAPT Therapeutics Beats EPS for Q4 2023
RAPT Therapeutics reported earnings per share of -80 cents. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -86 cents. RAPT did not have any revenue in the first quarter of 2014.
Investorplace · 03/07 19:52
RAPT Therapeutics GAAP EPS of -$0.80
RAPT Therapeutics reports Q4 GAAP EPS of -$0.80. The Company had cash and cash equivalents and marketable securities of $158.9 million as of December 31, 2023. Net loss for the fourth quarter of 2023 was $30.8 million.
Seeking Alpha · 03/07 16:25
RAPT Therapeutics: Q4 Earnings Insights
RAPT Therapeutics reported its Q4 earnings on March 7, 2024. The company beat estimates by $0.8. Last quarter the company missed on EPS by $ 0.07. RAPT's revenue was down $0 from the same period last year.
Benzinga · 03/07 14:25
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
NASDAQ · 03/07 13:36
RAPT Therapeutics Q4 EPS $(0.80) Beats $(0.86) Estimate, Cash Balance of $158.9M as of December 31, 2023
Benzinga · 03/07 13:06
*Rapt Therapeutics 4Q Research and Development Expenses $26.8M >RAPT
Dow Jones · 03/07 13:02
Press Release: RAPT Therapeutics Reports Fourth -2-
Assets include cash and cash equivalents, marketable securities, and other assets. Total assets are more than $200 million. Total liabilities are over $100 million. The company has a total of $266,000 million in assets and liabilities for the first quarter of 2014.
Dow Jones · 03/07 13:00
Press Release: RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results Company maintains solid cash position of $158.9 million. RAPT is a clinical-stage, immunology-based company focused on discovering, developing and commercializing oral small molecule therapies in inflammatory diseases and oncology. Company reported financial results for the fourth quarter and year ended December 31, 2023.
Dow Jones · 03/07 13:00
*Rapt Therapeutics 4Q Loss/Shr 80c >RAPT
Dow Jones · 03/07 13:00
RAPT Therapeutics Announces Multiple Late-Breaking Presentations At The Upcoming American Association For Cancer Research Annual Meeting
RAPT Therapeutics accepted three late-breaking abstracts for poster presentation at the American Association for Cancer Research Annual Meeting in 2024. The company's lead oncology drug candidate, tivumecirnon, will highlight phase 2 clinical data in head and neck squamous cell carcinoma. RAPT is a clinical-stage, immunology-based company focused on oral small molecule therapies.
Benzinga · 03/05 21:34
More
Webull provides a variety of real-time RAPT stock news. You can receive the latest news about Rapt Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RAPT
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.